A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)

Trial Profile

A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Pantoprazole
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis; Heart failure; Myocardial infarction; NSAID-induced gastrointestinal damage; Peripheral arterial disorders; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COMPASS; COMPASS CABG
  • Sponsors Bayer
  • Most Recent Events

    • 12 Mar 2018 Results of pooled analysis of ATLAS-ACS-TIMI-46, ATLAS-ACS-2-TIMI-51, GEMINI-ACS-1, and COMPASS trial comparing efficacy and safety of Rivaroxaban based dual pathway antithrombotic therapy Vs dual antiplatelet therapy presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 26 Feb 2018 According to a Janssen Pharmaceuticals media release, data will be presented at the American College of Cardiology's 67th Annual Scientific Session (ACC.18)
    • 26 Jan 2018 Results assessing the effects of Rivaroxaban with Aspirin on stroke disability, the predictors of stroke and the absolute reductions in stroke in patients at high risk, presented at the International Stroke Conference 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top